Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 36111560.
- Also identified by DOI 10.1093/infdis/jiac379 and PMC identifier 9494481.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated antibody titers and avidity after heterologous versus homologous coronavirus disease 2019 vaccination over 6 months after the second dose. We found a significantly higher avidity in regimens including at least 1 dose of the adenoviral vector vaccine ChAdOx1-S compared with 2 doses of the mRNA vaccine BNT162b2.
Medical subject headings
- Antibody Affinity
- BNT162 Vaccine
- COVID-19
- ChAdOx1 nCoV-19